Enovis (NYSE:ENOV) Upgraded by Wall Street Zen to “Buy” Rating

Enovis (NYSE:ENOV) was upgraded by Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Monday.

Several other equities analysts have also issued reports on ENOV. Zacks Research upgraded shares of Enovis from a “hold” rating to a “strong-buy” rating in a report on Wednesday, March 4th. UBS Group reaffirmed a “buy” rating and set a $50.00 price objective on shares of Enovis in a research report on Monday, January 5th. Evercore reiterated an “outperform” rating on shares of Enovis in a research note on Monday, January 12th. BTIG Research boosted their target price on Enovis from $41.00 to $43.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Finally, Needham & Company LLC increased their target price on Enovis from $49.00 to $52.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $47.43.

Enovis Stock Performance

Shares of ENOV stock opened at $21.86 on Monday. The company’s fifty day moving average price is $23.03 and its 200-day moving average price is $27.18. The stock has a market cap of $1.25 billion, a PE ratio of -1.06 and a beta of 1.46. The company has a current ratio of 2.02, a quick ratio of 1.04 and a debt-to-equity ratio of 0.85. Enovis has a 12 month low of $21.00 and a 12 month high of $38.56.

Enovis (NYSE:ENOV) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.81 by $0.14. Enovis had a negative net margin of 52.69% and a positive return on equity of 8.74%. The company had revenue of $575.76 million during the quarter, compared to analyst estimates of $584.30 million. During the same period last year, the business earned $0.98 EPS. Enovis’s quarterly revenue was up 2.6% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities analysts expect that Enovis will post 2.79 EPS for the current fiscal year.

Insider Activity at Enovis

In other news, insider Oliver Engert purchased 1,000 shares of Enovis stock in a transaction that occurred on Friday, February 27th. The stock was bought at an average price of $25.50 per share, with a total value of $25,500.00. Following the completion of the transaction, the insider directly owned 43,640 shares of the company’s stock, valued at approximately $1,112,820. The trade was a 2.35% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have purchased a total of 5,000 shares of company stock worth $121,983 in the last 90 days. Corporate insiders own 2.70% of the company’s stock.

Institutional Trading of Enovis

Institutional investors have recently added to or reduced their stakes in the business. Arax Advisory Partners purchased a new position in Enovis in the fourth quarter worth about $29,000. Farther Finance Advisors LLC lifted its stake in shares of Enovis by 42.8% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,224 shares of the company’s stock worth $37,000 after purchasing an additional 367 shares during the period. EverSource Wealth Advisors LLC lifted its stake in shares of Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after purchasing an additional 707 shares during the period. Elevation Point Wealth Partners LLC purchased a new position in shares of Enovis in the second quarter worth approximately $46,000. Finally, SJS Investment Consulting Inc. boosted its holdings in shares of Enovis by 30,340.0% in the third quarter. SJS Investment Consulting Inc. now owns 1,522 shares of the company’s stock worth $46,000 after buying an additional 1,517 shares during the last quarter. 98.45% of the stock is currently owned by hedge funds and other institutional investors.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.